Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human CD19-CD22 Targeted T Cells in CNS Involvement of Refractory/Relapsed B Cell Malignancies
NCT05651178Phase 1Active, not recruiting
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Human CD19-CD22 Targeted T Cells Injection in central nervous system lymphoma, B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma, sponsored by Shanghai HRAIN Biotechnology. Primary endpoints: Dose Limited Toxicity at 28 days and Adverse Events Grade >= 3 at 28 days. Started Aug 2022; status: active, not recruiting.
02
Drugs
Human CD19-CD22 Targeted T Cells Injection
03
Conditions
central nervous system lymphomaB cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT05651178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651178.